Publications
302 results found
Viola P, Maurya M, Croud J, et al., 2016, A validation study for the use of ROS-1 immunohistochemistry in screening for ROS-1 translocations in lung cancer, Journal of Thoracic Oncology, Vol: 11, Pages: 1029-1309, ISSN: 1556-1380
Introduction: The presence of ROS1 gene rearrangements in lung cancers confers sensitivity to ROS kinase inhibitors, including crizotinib. However, they are rare abnormalities (~1% in non-small cell lung carcinoma), typically identified via FISH, and so screening using immunohistochemistry (IHC) would be both cost and time-efficient.Methods: A cohort of lung tumours, negative for other common mutations related to targeted therapies, were screened to assess the sensitivity and specificity of IHC in detecting ROS1 gene rearrangements, enriched by four other cases first identified by FISH. A review of published data was also undertaken.Results: IHC was 100% (95% CI 48-100) sensitive and 83% (95% CI 86-100) specific overall when an h-score of >100 was used. Patients with ROS1 gene rearrangements were younger and typically never smokers, with the tumours all adenocarcinomas with higher grade architectural features and focal signet ring morphology (2/5). Four patients treated with crizotinib showed partial response, with three also showing partial response to pemetrexed. Three of four patients remain alive at 13, 27 and 31 months respectively.Conclusion: IHC can be used to screen for ROS1 gene rearrangements, with patients herein showing response to crizotinib. Patients with tumours positive with IHC but negative for FISH were also identified, which may have implications for treatment selection.
Siddiqui M, Bhoday J, Chand M, et al., 2016, THE ROLE OF CELL-FREE CIRCULATING TUMOR DNA (CTDNA) DEFINED BY KRAS AND TP53 MUTATIONS IN THE ASSESSMENT OF COLORECTAL CANCER RECURRENCE: A META-ANALYSIS., Annual Meeting of the American-Society-of-Colon-and-Rectal-Surgeons, Publisher: LIPPINCOTT WILLIAMS & WILKINS, Pages: E219-E220, ISSN: 0012-3706
Hua A, Pattenden H, Leung M, et al., 2016, Early cardiology assessment and intervention reduces mortality following myocardial injury after non-cardiac surgery (MINS), JOURNAL OF THORACIC DISEASE, Vol: 8, Pages: 920-924, ISSN: 2072-1439
- Author Web Link
- Cite
- Citations: 16
Lang P, Manickavasagar M, Burdett C, et al., 2016, Suction on chest drains following lung resection: evidence and practice are not aligned<SUP>aEuro</SUP>, EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, Vol: 49, Pages: 611-616, ISSN: 1010-7940
- Author Web Link
- Cite
- Citations: 38
Kumbasar U, Raubenheimer H, Al Sahaf M, et al., 2016, Selection for adjuvant chemotherapy in completely resected stage I non-small cell lung cancer: external validation of a Chinese prognostic risk model, Journal of Thoracic Disease, Vol: 8, Pages: 140-144, ISSN: 2077-6624
Background: The ability to sub-stratify survival within stage I is an important consideration as it is assumed that survival is heterogeneous within this sub-group. Liang et al. recently published a nomogram to predict post-operative survival in patients undergoing lung cancer surgery. The aim of our study is external validation of their published nomogram in a British cohort focusing on stages IA and IB to determine applicability in selection of adjuvant chemotherapy within stage I.Methods: Patient variables were extracted and the score individually calculated. Receiver operative characteristics curve (ROC) was calculated and compared with the original derivation cohort and the discriminatory ability was further quantified using survival plots by splitting our (external) validation cohort into three tertiles and Kaplan Meier plots were constructed and individual curves tested using Cox regression analysis on Stata 13 and R 3.1.2 respectively.Results: A total of 1,238 patients were included for analysis. For all patients from stage IA to IIB the mean (SD) score was 9.95 (4.2). The ROC score comparing patients who died versus those that remained alive was 0.62 (95% CI: 0.58 to 0.67). When divided into prognostic score tertiles, survival discrimination remained evident for the entire cohort, as well as those for stage IA and IB alone. The P value comparing survival between the middle and highest score with baseline (low score) was P=0.031 and P=0.034 respectively.Conclusions: Our results of external validation suggested lower survival discrimination than reported by the original group; however discrimination between survival remained evident for stage I.
Lim E, Brush T, Rogers C, 2016, Video assisted thoracoscopic lobectomy versus conventional Open LobEcTomy for lung cancer, a multi-centre randomised controlled trial with an internal pilot: the VIOLET study, 14th Annual British Thoracic Oncology Group Conference 2016, Publisher: Elsevier, Pages: S68-S69, ISSN: 1872-8332
Prolil C, Cufari ME, Raubenheimer H, et al., 2016, Can 30 day-mortality after lung cancer resection be used as an individual surgeon quality outcome? National data from the United Kingdom, 14th Annual British Thoracic Oncology Group Conference 2016, Publisher: Elsevier, Pages: S66-S66, ISSN: 1872-8332
De Sousa P, Barbosa M, Cufari ME, et al., 2016, Gene mutation profile of non-smokers compared to smokers participating in the CRUK stratified medicines programme at a single institution, 14th Annual British Thoracic Oncology Group Conference 2016, Publisher: Elsevier, Pages: S41-S41, ISSN: 1872-8332
Leung M, Freidina D, Nicholson A, et al., 2016, A comparative analysis of cancer hotspot mutation profiles in circulating tumour cells, circulating tumour DNA and matched primary lung tumour, 14th Annual British Thoracic Oncology Group Conference 2016, Publisher: Elsevier, Pages: S1-S1, ISSN: 1872-8332
Cufari ME, Proli C, Phull M, et al., 2016, Increasing incidence of non-smoking lung cancer: presentation of patients with early disease to a tertiary institution in the UK, Lung Cancer, Vol: 91, Pages: S17-S18, ISSN: 1872-8332
Leuzzi G, Rocco G, Ruffini E, et al., 2016, Multimodality therapy for locally advanced thymomas: A propensity score-matched cohort study from the European Society of Thoracic Surgeons Database, Journal of Thoracic and Cardiovascular Surgery, Vol: 151, Pages: 47-57.e1, ISSN: 0022-5223
ObjectiveThis study investigated the prognostic impact of multimodality therapies in locally advanced thymomas.MethodsFrom January 1990 to January 2010, clinicopathological, surgical, and oncological features were retrospectively reviewed in a cohort of 370 Masaoka-Koga stage III thymomas (World Health Organization classification A to B3) collected from 37 institutions. A multivariate Cox proportional hazard model was created to identify independent predictors of overall, cancer-specific (CSS), and relapse-free survivals. Furthermore, a propensity score–matching analysis for exposure to adjuvant (AT) therapy was generated.ResultsInduction therapy and AT were administered to 88 (24.9%) and 245 (69.4%) patients, respectively. Overall, 5- and 10-year overall survival, CSS, and relapse-free survivals were 82.8%, 88.4%, and 80.0%, and 68.9%, 83.3%, and 71.5%, respectively. At multivariable analysis performed in the matched cohort, AT was confirmed as the strongest predictive factor for overall survival (hazard ratio, 2.83; 95% confidence interval, 0.88-9.12; P = .08) and CSS (hazard ratio, 4.70; 95% confidence interval, 1.00-22.2; P = .05). Pathologic T classification (according to International Association for the Study of Lung Cancer and International Thymic Malignancy Interest Group TNM staging proposal) was an independent factor for relapse (hazard ratio, 8.69; 95% confidence interval, 1.08-70.04; P = .04). When CSS was adjusted for T classification, AT confirmed a significant survival advantage for pT3 tumors (P = .04). On the other hand, for thymomas larger than 5 cm, stratifying for tumor size and AT did not affect 5-year CSS (P = .17).ConclusionsOur results indicate that AT is beneficial for locally advanced thymomas, mainly for specific pathologic features (pT3 or tumor size smaller than 5 cm). Further larger studies are needed to confirm these data.
Bastin AJ, Davies N, Lim E, et al., 2016, Systemic inflammation and oxidative stress post-lung resection: effect of pretreatment with N-acetylcysteine, Respirology, Vol: 21, Pages: 180-187, ISSN: 1440-1843
Background and objectiveN-acetylcysteine has been used to treat a variety of lung diseases, where is it thought to have an antioxidant effect. In a randomized placebo-controlled double-blind study, the effect of N-acetylcysteine on systemic inflammation and oxidative damage was examined in patients undergoing lung resection, a human model of acute lung injury.MethodsEligible adults were randomized to receive preoperative infusion of N-acetylcysteine (240 mg/kg over 12 h) or placebo. Plasma thiols, interleukin-6, 8-isoprostane, ischaemia-modified albumin, red blood cell glutathione and exhaled breath condensate pH were measured pre- and post-operatively as markers of local and systemic inflammation and oxidative stress.ResultsPatients undergoing lung resection and one-lung ventilation exhibited significant postoperative inflammation and oxidative damage. Postoperative plasma thiol concentration was significantly higher in the N-acetylcysteine-treated group. However, there was no significant difference in any of the measured biomarkers of inflammation or oxidative damage, or in clinical outcomes, between N-acetylcysteine and placebo groups.ConclusionPreoperative administration of N-acetylcysteine did not attenuate postoperative systemic or pulmonary inflammation or oxidative damage after lung resection.
Lim E, He C-XM, 2015, Professor Eric Lim: blood-based genetic test, a brave try to detect non-smoking lung cancer, TRANSLATIONAL LUNG CANCER RESEARCH, Vol: 4, Pages: 825-827, ISSN: 2218-6751
Dietel M, Bubendorf L, Dingemans A-MC, et al., 2015, Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group, Thorax, Vol: 71, Pages: 177-184, ISSN: 0040-6376
Background There is currently no Europe-wide consensus on the appropriate preanalytical measures and workflow to optimise procedures for tissue-based molecular testing of non-small-cell lung cancer (NSCLC). To address this, a group of lung cancer experts (see list of authors) convened to discuss and propose standard operating procedures (SOPs) for NSCLC.Methods Based on earlier meetings and scientific expertise on lung cancer, a multidisciplinary group meeting was aligned. The aim was to include all relevant aspects concerning NSCLC diagnosis. After careful consideration, the following topics were selected and each was reviewed by the experts: surgical resection and sampling; biopsy procedures for analysis; preanalytical and other variables affecting quality of tissue; tissue conservation; testing procedures for epidermal growth factor receptor, anaplastic lymphoma kinase and ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) in lung tissue and cytological specimens; as well as standardised reporting and quality control (QC). Finally, an optimal workflow was described.Results Suggested optimal procedures and workflows are discussed in detail. The broad consensus was that the complex workflow presented can only be executed effectively by an interdisciplinary approach using a well-trained team.Conclusions To optimise diagnosis and treatment of patients with NSCLC, it is essential to establish SOPs that are adaptable to the local situation. In addition, a continuous QC system and a local multidisciplinary tumour-type-oriented board are essential.
Lim E, 2015, The devil is in the details: Managing chest drains and interpreting negative randomized trial data, JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, Vol: 150, Pages: 1252-1253, ISSN: 0022-5223
- Author Web Link
- Cite
- Citations: 2
McElnay PJ, Lim E, 2015, Training for single port video assisted thoracoscopic surgery lung resections, ANNALS OF TRANSLATIONAL MEDICINE, Vol: 3, ISSN: 2305-5839
- Author Web Link
- Cite
- Citations: 1
Mesa-Guzman M, Periklis P, Niwaz Z, et al., 2015, Determining optimal fluid and air leak cut off values for chest drain management in general thoracic surgery, JOURNAL OF THORACIC DISEASE, Vol: 7, Pages: 2053-2057, ISSN: 2072-1439
- Author Web Link
- Cite
- Citations: 14
Freidin MB, Freydina DV, Leung M, et al., 2015, Circulating Tumor DNA Outperforms Circulating Tumor Cells for KRAS Mutation Detection in Thoracic Malignancies, CLINICAL CHEMISTRY, Vol: 61, Pages: 1299-1304, ISSN: 0009-9147
- Author Web Link
- Cite
- Citations: 83
Leung M, Freidin M, Freidina D, et al., 2015, A Comparative Analysis of Cancer Hotspot Mutation Profiles in Circulating Tumour Cells, Circulating Tumour DNA and Matched Primary Lung Tumour, 16th World Conference on Lung Cancer, Publisher: Lippincott, Williams & Wilkins, Pages: S604-S604, ISSN: 1556-0864
Luciano G, Viola P, Al Sahaf M, et al., 2015, Is It Possible to Distinguish between Second Primary vs. Metastasis in Resectable Synchronous Nodules with the Same Histotype of Lung Cancer?, JOURNAL OF THORACIC ONCOLOGY, Vol: 10, Pages: S261-S261, ISSN: 1556-0864
Lim E, McElnay PJ, Rocco G, et al., 2015, Invasive mediastinal staging is irrelevant for PET/CT positive N2 lung cancer if the primary tumour and ipsilateral lymph nodes are resectable, LANCET RESPIRATORY MEDICINE, Vol: 3, Pages: E32-E33, ISSN: 2213-2600
- Author Web Link
- Cite
- Citations: 21
Cufari ME, Proli C, Phull M, et al., 2015, Increasing Incidence of Non-Smoking Lung Cancer: Presentation of Patients with Early Disease to a Tertiary Institution in the UK, JOURNAL OF THORACIC ONCOLOGY, Vol: 10, Pages: S793-S794, ISSN: 1556-0864
- Author Web Link
- Cite
- Citations: 1
Lu SK, Anbunathan H, Popat S, et al., 2015, Molecular Landscape of Malignant Mesothelioma from Whole Exome Sequencing, Publisher: ELSEVIER SCIENCE INC, Pages: S253-S253, ISSN: 1556-0864
Lim E, Freidin M, Freidina D, et al., 2015, Clinical Utility of a Blood Based Circulating Tumour DNA Signature for the Diagnosis of Lung Cancer, JOURNAL OF THORACIC ONCOLOGY, Vol: 10, Pages: S251-S251, ISSN: 1556-0864
Lim E, 2015, How do surgeons decide on the extent of resection for patients with lung cancer?, JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, Vol: 150, Pages: 458-459, ISSN: 0022-5223
Kumbasar U, Raubenheimer H, Al Sahaf M, et al., 2015, External Validation of a Chinese Developed Survival Score in a Western Cohort Undergoing Surgery for Non-Small Cell Lung Cancer, JOURNAL OF THORACIC ONCOLOGY, Vol: 10, Pages: S331-S331, ISSN: 1556-0864
Proli C, Cufari ME, Raubenheimer H, et al., 2015, Can 30-Mortality after Lung Cancer Resection Be Used as an Individual Surgeon Quality Outcome Internationally? National Data from the UK, JOURNAL OF THORACIC ONCOLOGY, Vol: 10, Pages: S493-S493, ISSN: 1556-0864
Filosso PL, Guerrera F, Evangelista A, et al., 2015, Prognostic model of survival for typical bronchial carcinoid tumours: analysis of 1109 patients on behalf of the European Association of Thoracic Surgeons (ESTS) Neuroendocrine Tumours Working Group, EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, Vol: 48, Pages: 441-447, ISSN: 1010-7940
- Author Web Link
- Cite
- Citations: 53
Cufari ME, Proli C, Phull M, et al., 2015, Is the Development of Primary Lung Adenocarcinoma Simply Due To 'Bad Luck'?, JOURNAL OF THORACIC ONCOLOGY, Vol: 10, Pages: S737-S737, ISSN: 1556-0864
Viola P, Maurya M, Croud J, et al., 2015, A Validation Study for the Use of ROS-1 Immunohistochemistry in Screening for ROS-1 Translocations in Lung Cancer, JOURNAL OF THORACIC ONCOLOGY, Vol: 10, Pages: S694-S694, ISSN: 1556-0864
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.